We recorded strong growth in sales and profitability, thanks especially to the acceleration of both our API Solutions and CDMO activities and to the execution of our industrial performance plan. We will continue to implement our strategic roadmap in the coming months and are confirming our guidance for full-year 2022 consolidated net sales and Core EBITDA margin.'
Business update
API Solutions' commercial strategy started to deliver in H1-2022. Several contracts with new and existing customers were signed, or extended, together with a strong level of activity on cross-selling. Against a backdrop of inflationary raw material and energy prices, price adjustment initiatives were accelerated and will materialize further in the second half of the year for the Other clients than
The CDMO strategy was deployed, with increased EUROAPI brand awareness on the market, intense prospection efforts with clients and strengthening of the scouting team. This resulted in the number of RFPs received in H1-2022 almost equaling the total number received in the whole of 2021. Construction of the CDMO project pipeline continued, with the number of projects now totaling 641 following the addition of 19 new projects, notably in oligonucleotides, lipid nanoparticles and complex chemistry. On
Several growth and performance capex projects were initiated in H1-2022 in line with the objective to commit about half of
About
Taking action for health by enabling access to essential therapies inspires our 3,350 people every day. With strong research and development capabilities and six manufacturing sites all located in
Contact:
Tel: +33 (0)6 81 86 80 19
Email: mr@euroapi.com
(C) 2022 Electronic News Publishing, source